Physician profile
Nadine E Graven
NPI 1295899847
$1,314.22
in general payments reported to CMS, 2019-2025
19 companies · $528 in 2025
The $528 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $36.29 · 2023: $262 · 2024: $488 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $379.38 | 2022-2025 | Bijuva, Annovera |
| Daiichi Sankyo INC. | $154.50 | 2023-2024 | Injectafer |
| Astellas Pharma US INC | $136.43 | 2024 | Veozah |
| Biogen, INC. | $96.83 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $96.10 | 2023-2024 | Ova1 |
| Hologic Sales and Service, LLC | $65.40 | 2022-2025 | Aptima |
| Pfizer INC. | $57.71 | 2023-2024 | |
| Shield Therapeutics INC | $45.85 | 2025 | |
| Evofem Biosciences, INC. | $43.42 | 2024-2025 | Phexxi, Solosec, Phexx |
| Coopersurgical, INC. | $38.43 | 2023 | Paragard T 380a, Mara Console |
| Boston Scientific Corporation | $29.84 | 2025 | Axonics |
| Ethicon US, LLC | $26.14 | 2023 | Stratafix, Dermabond Prineo |
| Becton, Dickinson and Company | $24.18 | 2023 | Bd Onclarity |
| Abbvie INC. | $22.72 | 2023 | |
| Organon LLC | $22.45 | 2025 | Nexplanon |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $18.91 | 2024 | Slynd |
| Minerva Surgical, INC | $18.76 | 2024 | |
| Sumitomo Pharma America, INC. | $18.65 | 2023 | Myfembree |
| Millicent US INC | $18.52 | 2025 | Intrarosa, Femring |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadine Graven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.